What is Guardant Health?
Liquid biopsy and cancer diagnostics company with 2026 revenue guidance of $1.25B-$1.28B scale.
- Category
- Liquid biopsy and cancer diagnostics
- Headquarters
- Palo Alto, CA
- Founded
- 2012
- Employees
- 2,500+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: GH
What is Guardant Health?
Guardant Health is a Liquid biopsy and cancer diagnostics company headquartered in Palo Alto, CA. As of June 2026, its clearest scale signal is 2026 revenue guidance of $1.25B-$1.28B.
Guardant Health operates a liquid-biopsy oncology diagnostics company with therapy selection, recurrence monitoring, biopharma, data, and Shield colorectal screening products. Its core customer set includes oncologists, cancer centers, patients, payers, biopharma companies, clinical-trial sponsors, and screening providers, and its public product surface includes Guardant360, Guardant360 CDx, Guardant Reveal, GuardantOMNI, GuardantINFINITY. The current scale signal is 2026 revenue guidance of $1.25B-$1.28B, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Guardant Health offer?
Guardant Health offers Guardant360, Guardant360 CDx, Guardant Reveal, GuardantOMNI and related healthcare workflows.
- Guardant360· Core product
- Guardant360 CDx· Core product
- Guardant Reveal· Core product
- GuardantOMNI· Workflow
- GuardantINFINITY· Workflow
- Shield colorectal screening· Workflow
- Smart Liquid Biopsy platform· Platform
- Biopharma data services· Platform
How does Guardant Health make money?
Guardant earns testing revenue from clinical oncology and screening volumes, biopharma services, data products, and reimbursement from Medicare, commercial payers, providers, or pharma customers.
Guardant earns testing revenue from clinical oncology and screening volumes, biopharma services, data products, and reimbursement from Medicare, commercial payers, providers, or pharma customers. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Diagnostic pricing is governed by CPT/reimbursement rates, payer coverage, test type, biopharma contracts, screening adoption, and contracted service terms rather than public SaaS tiers. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Guardant Health?
Guardant Health is led by Helmy Eltoukhy, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Helmy EltoukhyCo-founder, Chairman and Co-Chief Executive OfficerCo-founderLeads strategy and technology vision.
- AmirAli TalasazCo-founder and Co-Chief Executive OfficerCo-founderLeads scientific, product, and commercial execution.
- Mike BellChief Financial OfficerCFOOwns finance, capital allocation, and investor relations.
- Craig EagleChief Medical OfficerMedical leaderGuides clinical, medical, and evidence-generation strategy.
How do you contact Guardant Health's leadership?
Guardant Health publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@guardanthealth.com (official published/company IR contact); personal executive format not verifiedHow much funding has Guardant Health raised?
Guardant Health is a public company (Nasdaq: GH), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2012: Founded - Guardant Health is founded to advance blood-based cancer diagnostics. 2018: IPO - Guardant lists on Nasdaq under GH. 2020: FDA approval - Guardant360 CDx receives FDA approval for comprehensive genomic profiling. 2024: Shield approval - Shield becomes an FDA-approved blood-based colorectal cancer screening test. 2026: 2026 outlook - Guardant guides to $1.25B-$1.28B of 2026 revenue.
As of June 2026, Guardant Health's practical funding capacity is best read through Nasdaq: GH, 2026 revenue guidance of $1.25B-$1.28B, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Guardant Health access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Guardant Health get here?
Guardant Health grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2012Company foundedGuardant starts with a liquid-biopsy platform.
- 2018Public listingThe company lists on Nasdaq.
- 2020Guardant360 CDx approvalFDA approval strengthens therapy-selection credibility.
- 2022MRD and biopharma growthReveal and biopharma products broaden the platform.
- 2024Shield FDA approvalGuardant enters blood-based colorectal screening.
- 2026Revenue guidance above $1BManagement guides to $1.25B-$1.28B in 2026 revenue.
Who are Guardant Health's competitors?
Guardant Health competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- Exact SciencesCancer diagnostics peer with Cologuard and precision-oncology testing.
- NateraCell-free DNA testing company spanning oncology, women's health, and transplant.
- TempusAI-enabled precision-medicine platform with genomics, data, and clinical-trial products.
- Foundation MedicineRoche-owned comprehensive genomic profiling competitor.
- GRAILBlood-based multi-cancer early detection company.
- PersonalisPersonalized cancer genomics and MRD testing competitor.
Guardant Health — frequently asked questions
